Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Gooptu, Mahasweta  [Clear All Filters]
Journal Article
Vergara-Cadavid J, P Johnson C, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, et al. Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Ritz J, et al. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023.
Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin. Biol Blood Marrow Transplant. 2019.
Gooptu M, Bolaños-Meade J, Koreth J. Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond. Blood Rev. 2023:101053.
Shapiro RM, Birch GC, Hu G, Cadavid JVergara, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Gooptu M, Kim HT, Jacobsen ED, Fisher DC, Lacasce AS, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, et al. Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Adv. 2022.
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds CG, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
Chin K-K, Kim HT, Inyang E-A, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, et al. Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Maurer K, Ho VT, Inyang E, Cutler CS, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, et al. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023.
Bolaños-Meade J, Hamadani M, Wu J, Malki MMAl, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
Garcia JS, Kim HT, H Murdock M, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, et al. Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood Adv. 2024.
Thomas R, Madan R, Gooptu M, Hatabu H, Hammer MM. Significance of the Reverse Halo Sign in Immunocompromised Patients. AJR Am J Roentgenol. 2019:1-6.